Abstract：
BACKGROUND: Precision medicine has revolutionized oncology, providing more personalized diagnosis, treatment, and monitoring for patients with cancer. In the context of female-specific tumors, such as breast, ovarian, endometrial, and cervical cancer, proper tissue collection and handling are essential for obtaining tissue, immunohistochemical (IHC), and molecular data to guide therapeutic decisions.
OBJECTIVE: To establish guidelines for the collection and handling of tumor tissue, to enhance the quality of samples for histopathological, IHC, genomic, and molecular analyses. These guidelines are fundamental in informing therapeutic decisions in cancer treatment.
METHODS: The guidelines were developed by a multidisciplinary panel of renowned specialists between June 12, 2013 and February 12, 2024. Initially, the panel deliberated on critical and controversial topics related to conducting precision medicine studies focusing on female tumors. Subsequently, 22 pivotal topics were identified within the framework and assigned to groups. These groups reviewed relevant literature and drafted preliminary recommendations. Following this, the recommendations were reviewed by the coordinators and received unanimous approval. Finally, the groups made the final adjustments, classified the level of evidence, and ranked the recommendations.
CONCLUSIONS: The collection of surgical samples requires minimum quality standards to enable histopathological, IHC, genomic, and molecular analyses. These analyses provide crucial data for informing therapeutic decisions, significantly impacting potential survival gains for patients with female tumors.
OBJECTIVE: To establish guidelines for the collection and handling of tumor tissue, to enhance the quality of samples for histopathological, IHC, genomic, and molecular analyses. These guidelines are fundamental in informing therapeutic decisions in cancer treatment.
METHODS: The guidelines were developed by a multidisciplinary panel of renowned specialists between June 12, 2013 and February 12, 2024. Initially, the panel deliberated on critical and controversial topics related to conducting precision medicine studies focusing on female tumors. Subsequently, 22 pivotal topics were identified within the framework and assigned to groups. These groups reviewed relevant literature and drafted preliminary recommendations. Following this, the recommendations were reviewed by the coordinators and received unanimous approval. Finally, the groups made the final adjustments, classified the level of evidence, and ranked the recommendations.
CONCLUSIONS: The collection of surgical samples requires minimum quality standards to enable histopathological, IHC, genomic, and molecular analyses. These analyses provide crucial data for informing therapeutic decisions, significantly impacting potential survival gains for patients with female tumors.
摘要：
背景：精准医学彻底改变了肿瘤学，提供更个性化的诊断，治疗,和监测癌症患者。在女性特异性肿瘤的背景下，如乳房，卵巢,子宫内膜,还有宫颈癌,适当的组织收集和处理对于获得组织至关重要，免疫组织化学（IHC），和分子数据来指导治疗决策。
目的：为收集和处理肿瘤组织，为了提高组织病理学样本的质量，IHC,基因组，和分子分析。这些指南对于告知癌症治疗中的治疗决策至关重要。
方法：指南是由知名专家组成的多学科小组在2013年6月12日至2024年2月12日期间制定的。最初，小组讨论了与开展针对女性肿瘤的精准医学研究有关的关键和有争议的主题。随后，在框架内确定了22个关键主题，并将其分配给小组。这些小组审查了相关文献并起草了初步建议。在此之后,协调员审查了这些建议，并获得一致批准。最后,小组进行了最后的调整，对证据的级别进行分类，并对建议进行排名。
结论：手术样本的收集需要最低的质量标准，以使组织病理学，IHC,基因组，和分子分析。这些分析为指导治疗决策提供了重要数据，显着影响女性肿瘤患者的潜在生存率。
目的：为收集和处理肿瘤组织，为了提高组织病理学样本的质量，IHC,基因组，和分子分析。这些指南对于告知癌症治疗中的治疗决策至关重要。
方法：指南是由知名专家组成的多学科小组在2013年6月12日至2024年2月12日期间制定的。最初，小组讨论了与开展针对女性肿瘤的精准医学研究有关的关键和有争议的主题。随后，在框架内确定了22个关键主题，并将其分配给小组。这些小组审查了相关文献并起草了初步建议。在此之后,协调员审查了这些建议，并获得一致批准。最后,小组进行了最后的调整，对证据的级别进行分类，并对建议进行排名。
结论：手术样本的收集需要最低的质量标准，以使组织病理学，IHC,基因组，和分子分析。这些分析为指导治疗决策提供了重要数据，显着影响女性肿瘤患者的潜在生存率。
